DK0938486T3 - Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling - Google Patents

Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling

Info

Publication number: DK0938486T3
Authority: DK; Denmark
Prior art keywords: preparation; methods; substituted pyrrolopyrimidines; pyrrolopyrimidines; substituted
Prior art date: 1996-08-23

Application number

DK97940108T

Other languages

English (en)

Inventor

Peter Traxler

Guido Bold

Marc Lang

Joerg Frei

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-08-23

Filing date

1997-08-21

Publication date

2008-07-07

1997-08-21 Application filed by Novartis Ag filed Critical Novartis Ag

2008-07-07 Application granted granted Critical

2008-07-07 Publication of DK0938486T3 publication Critical patent/DK0938486T3/da

Links

150000004944 pyrrolopyrimidines Chemical class 0.000 title 1
JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical class N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 abstract 1
108091000080 Phosphotransferase Proteins 0.000 abstract 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
102000020233 phosphotransferase Human genes 0.000 abstract 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

DK97940108T 1996-08-23 1997-08-21 Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling DK0938486T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CH207196		1996-08-23
PCT/EP1997/004564 WO1998007726A1 (en)	1996-08-23	1997-08-21	Substituted pyrrolopyrimidines and processes for their preparation

Publications (1)

Publication Number	Publication Date
DK0938486T3 true DK0938486T3 (da)	2008-07-07

Family

ID=4225221

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK97940108T DK0938486T3 (da)	1996-08-23	1997-08-21	Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling

Country Status (11)

Country	Link
US (1)	US6180636B1 (da)
EP (1)	EP0938486B1 (da)
JP (1)	JP4242928B2 (da)
AT (1)	ATE384062T1 (da)
AU (1)	AU720429B2 (da)
CA (1)	CA2262421C (da)
DE (1)	DE69738468T2 (da)
DK (1)	DK0938486T3 (da)
ES (1)	ES2297864T3 (da)
PT (1)	PT938486E (da)
WO (1)	WO1998007726A1 (da)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6395733B1 (en) *	1995-06-07	2002-05-28	Pfizer Inc	Heterocyclic ring-fused pyrimidine derivatives
TR199801530T2 (xx)	1996-02-13	1998-11-23	Zeneca Limited	VEGF �nhibit�rleri olarak kinazolin t�revleri.
JP4464466B2 (ja)	1996-03-05	2010-05-19	アストラゼネカ・ユーケイ・リミテッド	４―アニリノキナゾリン誘導体
JP4205168B2 (ja)	1996-10-02	2009-01-07	ノバルティスアクチエンゲゼルシヤフト	ピリミジン誘導体およびその製造法
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
AP1411A (en)	1998-06-02	2005-05-10	Osi Pharm Inc	Pyrrolo[2,3d] pyrimidine compositions and their use.
US6878716B1 (en)	1998-06-02	2005-04-12	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptor and uses thereof
US6686366B1 (en)	1998-06-02	2004-02-03	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
PA8474101A1 (es) *	1998-06-19	2000-09-29	Pfizer Prod Inc	Compuestos de pirrolo [2,3-d] pirimidina
ID26698A (id)	1998-06-19	2001-02-01	Pfizer Prod Inc	SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA
UA71945C2 (en) *	1999-01-27	2005-01-17	Pfizer Prod Inc	Substituted bicyclic derivatives being used as anticancer agents
UA72946C2 (uk)	1999-11-05	2005-05-16	Астразенека Аб	Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
US6680322B2 (en)	1999-12-02	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
US6664252B2 (en)	1999-12-02	2003-12-16	Osi Pharmaceuticals, Inc.	4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US7160890B2 (en)	1999-12-02	2007-01-09	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
DK1235830T3 (da)	1999-12-10	2004-03-29	Pfizer Prod Inc	Pyrrolo[2,3-d]pyrimidin-forbindelser som proteinkinaseinhibitorer
GB0001930D0 (en)	2000-01-27	2000-03-22	Novartis Ag	Organic compounds
US7201891B1 (en) *	2000-05-19	2007-04-10	Otsuka Pharmaceutical Co., Ltd.	Pharmaceutical preparation for the diagnosis of helicobacter pylori infection
CA2412462A1 (en)	2000-06-14	2001-12-20	Warner-Lambert Company	6,5-fused bicyclic heterocycles
EE200200711A (et)	2000-06-26	2004-06-15	Pfizer Products Inc.	Pürrolo[2,3-d]pürimidiinühendid kui immunosupressiivsed vahendid
US6673802B2 (en)	2000-12-01	2004-01-06	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
US6680324B2 (en)	2000-12-01	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
GB0031080D0 (en) *	2000-12-20	2001-01-31	Novartis Ag	Organic compounds
US7301023B2 (en) *	2001-05-31	2007-11-27	Pfizer Inc.	Chiral salt resolution
US7323469B2 (en)	2001-08-07	2008-01-29	Novartis Ag	7H-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) *	2001-08-07	2001-10-03	Novartis Ag	Organic compounds
DE60234118D1 (de)	2001-11-30	2009-12-03	Osi Pharm Inc	Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
GT200200234A (es) *	2001-12-06	2003-06-27		Compuestos cristalinos novedosos
CN1620294A (zh)	2001-12-20	2005-05-25	Osi药物公司	嘧啶a2b选择性拮抗剂化合物,它们的合成及用途
US20030229067A1 (en)	2001-12-20	2003-12-11	Arlindo Castelhano	Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
AU2003250701A1 (en) *	2002-07-31	2004-02-16	Wayne R. Danter	Protein tyrosine kinase inhibitors
US20040121407A1 (en) *	2002-09-06	2004-06-24	Elixir Pharmaceuticals, Inc.	Regulation of the growth hormone/IGF-1 axis
DE60318089T2 (de) *	2002-10-09	2008-12-04	Critical Outcome Technologies, Inc.	Protein-tyrosine-kinase-inhibitoren
EP1572213A1 (en)	2002-11-26	2005-09-14	Pfizer Products Inc.	Method of treatment of transplant rejection
GB0403606D0 (en) *	2004-02-18	2004-03-24	Novartis Ag	Organic compounds
AU2005250285B2 (en) *	2004-06-02	2011-08-18	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
US7465726B2 (en) *	2004-08-02	2008-12-16	Osi Pharmaceuticals, Inc.	Substituted pyrrolo[2.3-B]pyridines
US8034815B2 (en)	2007-01-11	2011-10-11	Critical Outcome Technologies, Inc.	Compounds and method for treatment of cancer
CA2710039C (en)	2007-12-26	2018-07-03	Critical Outcome Technologies, Inc.	Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
NZ586642A (en)	2008-01-11	2012-04-27	Natco Pharma Ltd	Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
CA2730890C (en)	2008-07-17	2018-05-15	Critical Outcome Technologies Inc.	Thiosemicarbazone inhibitor compounds and cancer treatment methods
JP4884570B2 (ja)	2008-08-20	2012-02-29	ファイザー・インク	ピロロ［２，３−ｄ］ピリミジン化合物
US8385364B2 (en) *	2008-09-24	2013-02-26	Nec Laboratories America, Inc.	Distributed message-passing based resource allocation in wireless systems
WO2010054264A1 (en)	2008-11-07	2010-05-14	Triact Therapeutics, Inc.	Use of catecholic butane derivatives in cancer therapy
US20120189641A1 (en)	2009-02-25	2012-07-26	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
WO2010099137A2 (en)	2009-02-26	2010-09-02	Osi Pharmaceuticals, Inc.	In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099363A1 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (ja)	2009-02-27	2012-08-23	オーエスアイ・ファーマシューティカルズ，エルエルシー	間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US20120064072A1 (en)	2009-03-18	2012-03-15	Maryland Franklin	Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
AU2010279188A1 (en) *	2009-07-28	2012-02-23	Ube Industries, Ltd.	Pyrrolo[2,3-d]pyrimidine derivative
US20120316187A1 (en)	2009-11-13	2012-12-13	Pangaea Biotech, S.L.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
KR20120124428A (ko) *	2009-12-30	2012-11-13	아르퀼 인코포레이티드	치환된 피롤로-아미노피리미딘 화합물
US8987272B2 (en)	2010-04-01	2015-03-24	Critical Outcome Technologies Inc.	Compounds and method for treatment of HIV
EP2468883A1 (en)	2010-12-22	2012-06-27	Pangaea Biotech S.L.	Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
US9134297B2 (en)	2011-01-11	2015-09-15	Icahn School Of Medicine At Mount Sinai	Method and compositions for treating cancer and related methods
EP2492688A1 (en)	2011-02-23	2012-08-29	Pangaea Biotech, S.A.	Molecular biomarkers for predicting response to antitumor treatment in lung cancer
WO2012129145A1 (en)	2011-03-18	2012-09-27	OSI Pharmaceuticals, LLC	Nscle combination therapy
WO2012149014A1 (en)	2011-04-25	2012-11-01	OSI Pharmaceuticals, LLC	Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
DE102011111400A1 (de) *	2011-08-23	2013-02-28	Merck Patent Gmbh	Bicyclische heteroaromatische Verbindungen
JP6297490B2 (ja)	2011-08-31	2018-03-20	ジェネンテック，インコーポレイテッド	診断マーカー
WO2013055530A1 (en)	2011-09-30	2013-04-18	Genentech, Inc.	Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
WO2013190089A1 (en)	2012-06-21	2013-12-27	Pangaea Biotech, S.L.	Molecular biomarkers for predicting outcome in lung cancer
GB201223308D0 (en)	2012-12-21	2013-02-06	Univ Sunderland	Enzyme inhibitors
WO2014134202A1 (en)	2013-02-26	2014-09-04	Triact Therapeutics, Inc.	Cancer therapy
EP2976085A1 (en)	2013-03-21	2016-01-27	INSERM - Institut National de la Santé et de la Recherche Médicale	Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression
US9381246B2 (en)	2013-09-09	2016-07-05	Triact Therapeutics, Inc.	Cancer therapy
WO2015156674A2 (en)	2014-04-10	2015-10-15	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
MX2017008421A (es)	2014-12-24	2018-03-23	Genentech Inc	Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
US9630968B1 (en)	2015-12-23	2017-04-25	Arqule, Inc.	Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
JP2019530650A (ja)	2016-08-24	2019-10-24	アークルインコーポレイテッド	アミノ−ピロロピリミジノン化合物およびその使用方法
RS62456B1 (sr)	2016-12-22	2021-11-30	Amgen Inc	Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
JOP20190272A1 (ar)	2017-05-22	2019-11-21	Amgen Inc	مثبطات kras g12c وطرق لاستخدامها
US11548867B2 (en)	2017-07-19	2023-01-10	Idea Ya Biosciences, Inc.	Amido compounds as AhR modulators
SG11202001499WA (en)	2017-09-08	2020-03-30	Amgen Inc	Inhibitors of kras g12c and methods of using the same
US11045484B2 (en)	2018-05-04	2021-06-29	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
EP3788038B1 (en)	2018-05-04	2023-10-11	Amgen Inc.	Kras g12c inhibitors and methods of using the same
WO2019217691A1 (en)	2018-05-10	2019-11-14	Amgen Inc.	Kras g12c inhibitors for the treatment of cancer
US11096939B2 (en)	2018-06-01	2021-08-24	Amgen Inc.	KRAS G12C inhibitors and methods of using the same
EP3802537A1 (en)	2018-06-11	2021-04-14	Amgen Inc.	Kras g12c inhibitors for treating cancer
MX2020012261A (es)	2018-06-12	2021-03-31	Amgen Inc	Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
US20210393632A1 (en)	2018-10-04	2021-12-23	INSERM (Institut National de la Santé et de la Recherche Médicale)	Egfr inhibitors for treating keratodermas
JP2020090482A (ja)	2018-11-16	2020-06-11	アムジエン・インコーポレーテツド	Ｋｒａｓｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
CA3117222A1 (en)	2018-11-19	2020-05-28	Amgen Inc.	Kras g12c inhibitors and methods of using the same
JP7377679B2 (ja)	2018-11-19	2023-11-10	アムジエン・インコーポレーテツド	がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
MA54547A (fr)	2018-12-20	2022-03-30	Amgen Inc	Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
ES2953821T3 (es)	2018-12-20	2023-11-16	Amgen Inc	Inhibidores de KIF18A
MA54546A (fr)	2018-12-20	2022-03-30	Amgen Inc	Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
PE20211475A1 (es)	2018-12-20	2021-08-05	Amgen Inc	Inhibidores de kif18a
CN113874015A (zh)	2018-12-21	2021-12-31	细胞基因公司	Ripk2的噻吩并吡啶抑制剂
JP2022522777A (ja)	2019-03-01	2022-04-20	レボリューションメディシンズインコーポレイテッド	二環式ヘテロアリール化合物及びその使用
US20230096028A1 (en)	2019-03-01	2023-03-30	Revolution Medicines, Inc.	Bicyclic heterocyclyl compounds and uses thereof
AU2020274083A1 (en) *	2019-05-13	2021-11-18	D.E. Shaw Research, Llc	FGFR inhibitors and methods of use thereof
EP3738593A1 (en)	2019-05-14	2020-11-18	Amgen, Inc	Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en)	2019-05-21	2022-03-30	Amgen Inc.	Solid state forms
WO2021026098A1 (en)	2019-08-02	2021-02-11	Amgen Inc.	Kif18a inhibitors
AU2020324963A1 (en)	2019-08-02	2022-02-24	Amgen Inc.	KIF18A inhibitors
US20220372018A1 (en)	2019-08-02	2022-11-24	Amgen Inc.	Kif18a inhibitors
CN114401953A (zh)	2019-08-02	2022-04-26	美国安进公司	Kif18a抑制剂
WO2021081212A1 (en)	2019-10-24	2021-04-29	Amgen Inc.	Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
CA3159559A1 (en)	2019-11-04	2021-05-14	Revolution Medicines, Inc.	Ras inhibitors
TW202132314A (zh)	2019-11-04	2021-09-01	美商銳新醫藥公司	Ｒａｓ抑制劑
EP4054719A1 (en)	2019-11-04	2022-09-14	Revolution Medicines, Inc.	Ras inhibitors
PE20230249A1 (es)	2019-11-08	2023-02-07	Revolution Medicines Inc	Compuestos de heteroarilo biciclicos y usos de estos
WO2021097212A1 (en)	2019-11-14	2021-05-20	Amgen Inc.	Improved synthesis of kras g12c inhibitor compound
AR120456A1 (es)	2019-11-14	2022-02-16	Amgen Inc	Síntesis mejorada del compuesto inhibidor de g12c de kras
JP2023505100A (ja)	2019-11-27	2023-02-08	レボリューションメディシンズインコーポレイテッド	共有ｒａｓ阻害剤及びその使用
BR112022010086A2 (pt)	2020-01-07	2022-09-06	Revolution Medicines Inc	Dosagem do inibidor de shp2 e métodos de tratamento de câncer
CN115916194A (zh)	2020-06-18	2023-04-04	锐新医药公司	用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
US11814388B1 (en) *	2020-08-28	2023-11-14	Ferris State University	Substituted pyrrolo[2,3-d]pyrimidines and pyrazolo[3,4-d]pyrimidines as inhibitors for multi-resistant cancers
AU2021344830A1 (en)	2020-09-03	2023-04-06	Revolution Medicines, Inc.	Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
KR20230067635A (ko)	2020-09-15	2023-05-16	레볼루션 메디슨즈, 인크.	암의 치료에서 ras 억제제로서 인돌 유도체
CN117396472A (zh)	2020-12-22	2024-01-12	上海齐鲁锐格医药研发有限公司	Sos1抑制剂及其用途
WO2022235054A1 (ko) *	2021-05-03	2022-11-10	주식회사 제이비케이랩	2,6-디클로로-4-(4-(4-하이드록시사이클로헥실아미노)-7h-피롤로[2,3-d]피리미딘-5-일)페놀을 유효성분으로 포함하는 암의 예방, 개선 또는 치료용 약학적 조성물
CN117500811A (zh)	2021-05-05	2024-02-02	锐新医药公司	共价ras抑制剂及其用途
CR20230570A (es)	2021-05-05	2024-01-22	Revolution Medicines Inc	Inhibidores de ras
WO2022235870A1 (en)	2021-05-05	2022-11-10	Revolution Medicines, Inc.	Ras inhibitors for the treatment of cancer
AR127308A1 (es)	2021-10-08	2024-01-10	Revolution Medicines Inc	Inhibidores ras
TW202340214A (zh)	2021-12-17	2023-10-16	美商健臻公司	做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (en)	2022-02-11	2023-08-16	Genzyme Corporation	Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en)	2022-03-08	2023-09-14	Revolution Medicines, Inc.	Methods for treating immune refractory lung cancer
WO2023240263A1 (en)	2022-06-10	2023-12-14	Revolution Medicines, Inc.	Macrocyclic ras inhibitors
WO2024081916A1 (en)	2022-10-14	2024-04-18	Black Diamond Therapeutics, Inc.	Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
CN116332940A (zh) *	2023-02-14	2023-06-27	广西民族大学	一种7-脱氮嘌呤衍生物及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3036930C2 (de)	1980-09-30	1982-06-16	Windmöller & Hölscher, 4540 Lengerich	Ungleichförmigkeitsgetriebe, vorzugsweise zum Antrieb von Messerwalzen
US5661148A (en) *	1989-09-19	1997-08-26	Teijin Limited	Pyrrolo[2,3-d]pyrimidine derivatives, process for producing the same and pharmaceutical preparation comprising the same as active ingredient
SG64322A1 (en)	1991-05-10	1999-04-27	Rhone Poulenc Rorer Int	Bis mono and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5654307A (en) *	1994-01-25	1997-08-05	Warner-Lambert Company	Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112248A0 (en)	1994-01-25	1995-03-30	Warner Lambert Co	Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en)	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
EP0682027B1 (de)	1994-05-03	1997-10-15	Novartis AG	Pyrrolopyrimidinderivate mit antiproliferativer Wirkung
ATE199553T1 (de)	1994-09-29	2001-03-15	Novartis Erfind Verwalt Gmbh	Pyrrolo(2,3-d)pyrimidinderivate und ihre verwendung
EP0819129B1 (en)	1995-04-03	2000-08-02	Novartis AG	Pyrazole derivatives and processes for the preparation thereof
US6403599B1 (en)	1995-11-08	2002-06-11	Pfizer Inc	Corticotropin releasing factor antagonists
WO1996040142A1 (en)	1995-06-07	1996-12-19	Pfizer Inc.	Heterocyclic ring-fused pyrimidine derivatives
SI9620103A (sl)	1995-07-06	1998-10-31	Novartis Ag	Pirolopirimidini in postopki za njihovo pripravo
AU1441497A (en)	1996-01-23	1997-08-20	Novartis Ag	Pyrrolopyrimidines and processes for their preparation
GB9604361D0 (en)	1996-02-29	1996-05-01	Pharmacia Spa	4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU4779897A (en)	1996-10-02	1998-04-24	Novartis Ag	Fused pyrazole derivatives and processes for their preparation
JP4205168B2 (ja)	1996-10-02	2009-01-07	ノバルティスアクチエンゲゼルシヤフト	ピリミジン誘導体およびその製造法

1997
- 1997-08-21 JP JP51042598A patent/JP4242928B2/ja not_active Expired - Fee Related
- 1997-08-21 ES ES97940108T patent/ES2297864T3/es not_active Expired - Lifetime
- 1997-08-21 AU AU42064/97A patent/AU720429B2/en not_active Ceased
- 1997-08-21 PT PT97940108T patent/PT938486E/pt unknown
- 1997-08-21 DK DK97940108T patent/DK0938486T3/da active
- 1997-08-21 DE DE69738468T patent/DE69738468T2/de not_active Expired - Lifetime
- 1997-08-21 EP EP97940108A patent/EP0938486B1/en not_active Expired - Lifetime
- 1997-08-21 US US09/242,592 patent/US6180636B1/en not_active Expired - Fee Related
- 1997-08-21 WO PCT/EP1997/004564 patent/WO1998007726A1/en active IP Right Grant
- 1997-08-21 CA CA002262421A patent/CA2262421C/en not_active Expired - Fee Related
- 1997-08-21 AT AT97940108T patent/ATE384062T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
PT938486E (pt)	2008-03-27
EP0938486B1 (en)	2008-01-16
EP0938486A1 (en)	1999-09-01
ES2297864T3 (es)	2008-05-01
WO1998007726A1 (en)	1998-02-26
DE69738468T2 (de)	2009-01-08
AU4206497A (en)	1998-03-06
DE69738468D1 (de)	2008-03-06
AU720429B2 (en)	2000-06-01
US6180636B1 (en)	2001-01-30
JP2000516626A (ja)	2000-12-12
CA2262421A1 (en)	1998-02-26
JP4242928B2 (ja)	2009-03-25
CA2262421C (en)	2007-10-02
ATE384062T1 (de)	2008-02-15

Publication	Publication Date	Title
DK0938486T3 (da)	2008-07-07	Substituerede pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
AU4864297A (en)	1998-04-24	Pyrimidine derivatives and processes for the preparation thereof
DK0836605T3 (da)	2002-05-13	Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
DK0819129T3 (da)	2000-10-23	Pyrazolderivater og fremgangsmåde til deres fremstilling
EE03770B1 (et)	2002-06-17	Pürido[2,3-d]pürimidiinid kui türosiinkinaas-valgu poolt vahendatava rakkude proliferatsiooni inhibiitorid, farmatseutiline kompositsioon, kasutamine
TR199900048T2 (xx)	1999-04-21	Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
NZ516292A (en)	2004-01-30	Pyrrolotriazine inhibitors of kinases
GEP20074227B (en)	2007-10-25	PYRROLO [2,3-d] PYRIMIDINE COMPOUNDS
ATE244719T1 (de)	2003-07-15	N-7 heterocyclyl-pyrrolo( 2,3-d)pyrimidine und ihre verwendung
DK0783505T3 (da)	2001-07-02	Pyrrolo[2,3-d]pyrimidiner og deres anvendelse
FI972492A0 (fi)	1997-06-12	Imidatsolijohdoksia proteiinikinaasien, erityisesti EGF-R-tyrosiinikinaasin, inhibiittoreina
MX9305833A (es)	1994-06-30	Procedimiento para la preparacion de pirrolo[2,3-d]pirimidinas 5-sustituidas.
NO871024D0 (no)	1987-03-12	Pyrazolo(3,4-d)pyrimidinderivater og fremgangsmaate for deres fremstilling.
IT1313593B1 (it)	2002-09-09	Derivati di 1,2-diidro-1-oxo-pirazino 1,2-a indolo.
DE60036955D1 (de)	2007-12-13	HERSTELLUNG VON i3,5,7ö-1H-IMIDAZOi1,5-AöIMIDAZOL-2(3H)-ON-VERBINDUNGEN
DE69630561D1 (de)	2003-12-11	Verwendung von 4-Amino-6-hydroxypyrazolo[3,4-d]pyrimidin zur Herstellung eines blutdrucksenkenden Mittels
ECSP972276A (es)	1998-11-30	Derivados de pirazol condensado y procesado para su preparacion
MY104960A (en)	1994-07-30	4-substituted pyrazolo (3,4-d) pyrimidine derivatives.
EP1842851A3 (en)	2008-02-27	Novel compounds